Analysis for PM
$199.90
-5.68
(-2.76%)
- 📈 Growth — 26/30
- 💰 Profitability — 16/20
- 🏦 Financial Health — 12/20
- 💵 Valuation — 13/20
- ⚠️ Risk — 6/10
Overall Score: 71/100
Summary:
📈 Growth & Financial Trajectory
In 8 quarters, Revenues rose from $9.468B (2024 Q2) to $11.192B (2026 Q2), a multi-quarter upswing. Net Income advanced from about $2.53B to $2.99B, signaling improving profitability despite quarterly fluctuations.
💰 Margins & Cash Flow
- Gross Margin remained strong around 65–71%, with mix and cost controls supporting solid operating results.
- Operating cash flow from continuing activities was robust, generally in the $4.0–5.5B range; investing activity was mixed and financing often negative, creating varying total net cash flow across quarters.
🛡️ Balance Sheet & Liquidity
- Assets of about $65–69B vs Liabilities of $65–78B; Equity persistently negative around -$7.7B to -$9.4B, indicating leverage but supported by ongoing cash generation.
- Current assets vs current liabilities yield a near-1x liquidity profile, reflecting modest cushion in working capital.
⚠️ Key Drivers & Risks
- Drivers: steady tobacco demand and geographic diversification; pricing power and dividend-focused cash generation.
- Risks: regulatory and litigation exposure; leverage/negative equity dynamics and currency movements.
📊 Key Financial Fundamentals
Valuation Multiples
Market Cap
$298.80B
P/E Ratio
27.48
Forward P/E
21.73
P/S Ratio
7.02
P/B Ratio
1,368.86
EV / EBITDA
19.16
Profitability & Returns
Gross Margin
67.51%
Operating Margin
37.75%
Net Margin
25.56%
ROE
575.44%
ROIC
44.05%
Financial Health & Liquidity
Current Ratio
0.98
Quick Ratio
0.98
Financial Scale & Cash Flow
Revenue
$42.54B
Net Income
$10.87B
FCF Yield
4.51%
Free Cash Flow
$13.47B
Total Debt To Equity
186.08